Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Stocks closed higher on Wall Street as the Trump administration sought to win more deals with global trading partners ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Susman shared Tuesday that she’ll be stepping down from her role as EVP and chief corporate affairs officer after 18 years with the company. Susman joined Pfizer in 2007 and helped lead the company ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...